Conditions & Recovery · ScienceDaily — Cancer · June 25, 2026

FDA-approved drug may finally help immunotherapy defeat rare liver cancer

Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.

Originally published by ScienceDaily — Cancer. We curate and add context; they did the reporting.

Related learning